Defendant Name: ReShape Lifesciences Inc.

Defendant Type: Public Company
SIC Code: 9999
CUSIP: 76090R20

Initial Case Details

Legal Case Name In the Matter of ReShape Lifesciences Inc.
First Document Date 22-Aug-2023
Initial Filing Format Administrative Action
File Number 3-21576
Allegation Type Issuer Reporting and Disclosure
AAER 4447

Violations Alleged

Exchange Act
• Sec 13(a)
Other
• Rule 12b-25 Exchange Act

Resolutions

First Resolution Date 22-Aug-2023
Headline Total Penalty and Disgorgement $35,000

Related Documents:

34-98193 22-Aug-2023 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On August 22, 2023, the SEC instituted cease-and-desist proceedings against ReShape Lifesciences Inc., stating: "These proceedings arise out of the violation of Exchange Act Rule 12b-25, which requires that issuers of a security registered pursuant to Section 12 of the Exchange Act that fail to file timely a periodic report shall file a Form 12b-25 “Notification of Late Filing,” commonly known as “Form NT,” which contains, among other things, reasonable detail as to why the issuer’s periodic report could not be filed on time and an explanation of any anticipated, significant changes in the issuer’s results of operations."
34-98193-s 22-Aug-2023 Administrative Summary
SEC Charges Five Companies for Failure to Disclose Complete Information on Form NT
On August 22, 2023, the SEC stated that: "[It] charged five companies for failing to disclose in SEC Form 12b-25 filings that their request for seeking a delayed quarterly or annual reporting filing was caused by an anticipated restatement or correction of prior financial reporting. Each of the companies was a public reporting company at the time of the violations and agreed to settle the Commission's charges and pay civil penalties. In April 2021, the Commission identified and charged eight companies for similar violations"